Literature DB >> 32051208

Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?

Pedro Marcos1,2, Gisela Brito-Gonçalves3, Diogo Libânio4,5, Inês Pita4, Rui Castro4, Inês Sá4, Mário Dinis-Ribeiro4,5, Pedro Pimentel-Nunes4,5,6.   

Abstract

OBJECTIVES: To assess the value of endoscopic grading of gastric intestinal metaplasia (EGGIM), operative link on gastritis assessment (OLGA) and operative link on gastric intestinal metaplasia (OLGIM) on risk stratification for early gastric neoplasia (EGN) and to investigate other factors possibly associated with its development.
DESIGN: Single centre, case-control study including 187 patients with EGN treated endoscopically and 187 age-matched and sex-matched control subjects. Individuals were classified according to EGGIM, OLGA and OLGIM systems. EGN risk according to gastritis stages and other clinical parameters was further evaluated.
RESULTS: More patients with EGN had EGGIM of ≥5 than control subjects (68.6% vs 13.3%, p<0.001). OLGA and OLGIM stages III/IV were more prevalent in patients with EGN than in control subjects (68% vs 11%, p<0.001, and 61% vs 3%, p<0.001, respectively). The three systems were the only parameters significantly related to the risk of EGN in multivariate analysis: for EGGIM 1-4 (adjusted OR (AOR) 12.9, 95% CI 1.4 to 118.6) and EGGIM 5-10 (AOR 21.2, 95% CI 5.0 to 90.2); for OLGA I/II (AOR 5.0, 95% CI 0.56 to 44.5) and OLGA III/IV (AOR 11.1, 95% CI 3.7 to 33.1); for OLGIM I/II (AOR 11.5, 95% CI 4.1 to 32.3) and OLGIM III/IV (AOR 16.0, 95% CI 7.6 to 33.4).
CONCLUSION: This study confirms the role of histological assessment as an independent risk factor for gastric cancer (GC), but it is the first study to show that an endoscopic classification of gastric intestinal metaplasia is highly associated with that outcome. After further prospective validation, this classification may be appropriate for GC risk stratification and may simplify every day practice by reducing the need for biopsies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  endoscopy; gastric cancer; gastric intestinal metaplasia; gastritis

Mesh:

Year:  2020        PMID: 32051208     DOI: 10.1136/gutjnl-2019-320091

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

1.  Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer.

Authors:  Monika Laszkowska; Han Truong; Adam S Faye; Judith Kim; Sarah Xinhui Tan; Francesca Lim; Julian A Abrams; Chin Hur
Journal:  Dig Dis Sci       Date:  2021-10-17       Impact factor: 3.487

2.  Biopsy Sampling in Upper Gastrointestinal Endoscopy: A Survey from 10 Tertiary Referral Centres Across Europe.

Authors:  Jan Bornschein; Terry Tran-Nguyen; Gloria Fernandez-Esparrach; Stephen Ash; Francesc Balaguer; Elizabeth L Bird-Lieberman; Henry Córdova; Zane Dzerve; Matteo Fassan; Marcis Leja; Ivan Lyutakov; Tim Middelburg; Leticia Moreira; Radislav Nakov; Stella A V Nieuwenburg; Anthony O'Connor; Stefano Realdon; Heiko De Schepper; Annemieke Smet; M C W Spaander; Ivars Tolmanis; Tadas Urbonas; Jochen Weigt; Georgina L Hold; Alexander Link; Juozas Kupcinskas
Journal:  Dig Dis       Date:  2020-10-01       Impact factor: 2.404

3.  Endoscopic diagnosis of gastric intestinal metaplasia in patients with autoimmune gastritis using narrow-band imaging: does pseudopyloric metaplasia muddy the waters?

Authors:  Emanuele Dilaghi; Gianluca Esposito; Giulia Pivetta; Gloria Galli; Emanuela Pilozzi; Bruno Annibale; Edith Lahner
Journal:  Endosc Int Open       Date:  2022-04-14

Review 4.  Improving the Diagnosis and Treatment of Early Gastric Cancer in the West.

Authors:  Diogo Libânio; Raquel Ortigão; Pedro Pimentel-Nunes; Mário Dinis-Ribeiro
Journal:  GE Port J Gastroenterol       Date:  2021-12-07

5.  hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer.

Authors:  Peng Xu; Xiaolan Xu; Lixiang Zhang; Zhengnan Li; Jianjun Qiang; Jie Yao; Aman Xu
Journal:  Oncol Lett       Date:  2021-06-24       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.